Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Contributed by: Business Wire

Logo

Tags

Biotechnology

FDA

Other Health

Health

General Health

Pharmaceutical

Mental Health

Other Science

Research

Science

Clinical Trials

Compass Pathfinder Limited

More Like This

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials